135 related articles for article (PubMed ID: 28851416)
1. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
[TBL] [Abstract][Full Text] [Related]
2. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
[TBL] [Abstract][Full Text] [Related]
3. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration.
Bailey CN; Martin BJ; Petkov VI; Schussler NC; Stevens JL; Bentler S; Cress RD; Doherty JA; Durbin EB; Gomez SL; Gonsalves L; Hernandez BY; Liu L; Morawski BM; Schymura MJ; Schwartz SM; Ward KC; Wiggins C; Wu XC; Goldberg MS; Siegel JJ; Cook RW; Covington KR; Kurley SJ
JCO Precis Oncol; 2023 Jun; 7():e2300044. PubMed ID: 37384864
[TBL] [Abstract][Full Text] [Related]
4. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma.
Miguez S; Lee RY; Chan AX; Demkowicz PC; Jones BSCL; Long CP; Abramson DH; Bosenberg M; Sznol M; Kluger H; Goldbaum MH; Francis JH; Pointdujour-Lim R; Bakhoum MF
Ophthalmology; 2023 Jun; 130(6):598-607. PubMed ID: 36739981
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.
Cai L; Paez-Escamilla M; Walter SD; Tarlan B; Decatur CL; Perez BM; Harbour JW
Am J Ophthalmol; 2018 Nov; 195():154-160. PubMed ID: 30092184
[TBL] [Abstract][Full Text] [Related]
8. Primary dermal melanoma: a unique subtype of melanoma to be distinguished from cutaneous metastatic melanoma: a clinical, histologic, and gene expression-profiling study.
Sidiropoulos M; Obregon R; Cooper C; Sholl LM; Guitart J; Gerami P
J Am Acad Dermatol; 2014 Dec; 71(6):1083-92. PubMed ID: 25262174
[TBL] [Abstract][Full Text] [Related]
9. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies.
Dhillon S; Duarte-Bateman D; Fowler G; Hagstrom MNE; Lampley N; Olivares S; Fumero-Velázquez MS; Vu K; Wayne JD; Gastman BR; Vetto J; Gerami P
Arch Dermatol Res; 2023 Oct; 315(8):2295-2302. PubMed ID: 36977840
[TBL] [Abstract][Full Text] [Related]
10. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma.
Karjalainen JM; Tammi RH; Tammi MI; Eskelinen MJ; Agren UM; Parkkinen JJ; Alhava EM; Kosma VM
Am J Pathol; 2000 Sep; 157(3):957-65. PubMed ID: 10980134
[TBL] [Abstract][Full Text] [Related]
11. Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma.
Hu Y; Briggs A; Marchetti MA; Ariyan CE; Coit DG; Bartlett EK
J Am Coll Surg; 2020 Nov; 231(5):547-554.e1. PubMed ID: 32889093
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
[TBL] [Abstract][Full Text] [Related]
13. Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study.
Plasseraud KM; Cook RW; Tsai T; Shildkrot Y; Middlebrook B; Maetzold D; Wilkinson J; Stone J; Johnson C; Oelschlager K; Aaberg TM
J Oncol; 2016; 2016():5325762. PubMed ID: 27446211
[TBL] [Abstract][Full Text] [Related]
14. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Wysong A; Somani AK; Ibrahim SF; Cañueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
[TBL] [Abstract][Full Text] [Related]
15. Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma.
Suwajanakorn D; Lane AM; Go AK; Hartley CD; Oxenreiter M; Wu F; Gragoudas ES; Sullivan RJ; Montazeri K; Kim IK
Melanoma Res; 2024 Apr; ():. PubMed ID: 38578293
[TBL] [Abstract][Full Text] [Related]
16. Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma.
Zainulabadeen A; Yao P; Zare H
PLoS One; 2017; 12(1):e0170025. PubMed ID: 28114321
[TBL] [Abstract][Full Text] [Related]
17. Telomere length and survival in primary cutaneous melanoma patients.
Rachakonda S; Srinivas N; Mahmoudpour SH; Garcia-Casado Z; Requena C; Traves V; Soriano V; Cardelli M; Pjanova D; Molven A; Gruis N; Nagore E; Kumar R
Sci Rep; 2018 Jul; 8(1):10947. PubMed ID: 30026606
[TBL] [Abstract][Full Text] [Related]
18. Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance?
Zager JS; Hyams DM
Clin Exp Metastasis; 2023 Dec; ():. PubMed ID: 38064126
[TBL] [Abstract][Full Text] [Related]
19. Loss in life expectancy in patients with stage II-III cutaneous melanoma in Sweden: A population-based cohort study.
Vikström S; Syriopoulou E; Andersson TM; Eriksson H
J Am Acad Dermatol; 2024 May; 90(5):963-969. PubMed ID: 38218560
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020.
Davidson TM; Hieken TJ; Glasgow AE; Habermann EB; Yan Y
Melanoma Res; 2024 Apr; 34(2):175-181. PubMed ID: 38265469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
